Starpharma HoldingsASX:SPL -1.38%53 Cyclically Adjusted PS Ratio is 71.50 as of Jul. 07, 2026, which is 5% below its 10-year median of 75.25. GuruFocus rates ASX:SPL with a GF Score™ of 53/100 and a GF Value™ of A$0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 535 Biotechnology companies, Starpharma Holdings ranks worse than 92.15% on this metric.
The historical rank and industry rank for Starpharma Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:
ASX:SPL'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.7 Med: 75.25 Max: 236
Current: 60.68
During the past 13 years, Starpharma Holdings's highest Cyclically Adjusted PS Ratio was 236.00. The lowest was 8.70. And the median was 75.25.
ASX:SPL's Cyclically Adjusted PS Ratio is ranked worse than 92.15% of 535
companies
in the Biotechnology industry
Industry Median: 5.95
vs ASX:SPL: 60.68
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Starpharma Holdings's adjusted revenue per share data of for the fiscal year that ended in Jun25 was A$0.012. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is A$0.01 for the trailing ten years ended in Jun25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Starpharma Holdings (ASX:SPL) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Starpharma Holdings Cyclically Adjusted PS Ratio Related Terms
Starpharma Holdings Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Starpharma Holdings's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings Cyclically Adjusted PS Ratio Chart
ASX:SPL vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Starpharma Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starpharma Holdings Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Starpharma Holdings's Cyclically Adjusted PS Ratio falls into.
Starpharma Holdings Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Starpharma Holdings's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 71.50 mean?
Starpharma Holdings (ASX:SPL) has a Cyclically Adjusted PS Ratio of 71.50 as of Jul. 07, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Starpharma Holdings and its competitors. This is near median its historical median of 75.25. Over the past decade, Starpharma Holdings' Cyclically Adjusted PS Ratio has ranged from 8.70 to 236.00. According to the industry distribution chart, Starpharma Holdings ranks #493 out of 535 companies in the Biotechnology industry, placing it in the top 92.1%.
Is Starpharma Holdings' Cyclically Adjusted PS Ratio too high?
Starpharma Holdings' current Cyclically Adjusted PS Ratio of 71.50 is near median its 10-year median of 75.25. Over the past 10 years, this metric has ranged from a low of 8.70 to a high of 236.00. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.95. Starpharma Holdings' value of 71.50 is 1101.7% above this industry median. Based on the distribution chart, Starpharma Holdings ranks #493 out of 535 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #493 out of 535 companies for Cyclically Adjusted PS Ratio. This places Starpharma Holdings in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.95. Starpharma Holdings' value of 71.50 is 1101.7% above this benchmark. Historically, Starpharma Holdings' own Cyclically Adjusted PS Ratio has ranged from 8.70 to 236.00 over the past decade. While the company's 10-year median is 75.25 vs. the industry median of 5.95, Starpharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.95, based on 535 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Starpharma Holdings's current Cyclically Adjusted PS Ratio of 71.50 is 1101.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Starpharma Holdings and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starpharma Holdings's current Cyclically Adjusted PS Ratio is 71.50, which is near median its own 10-year median of 75.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.44, compared to a current price of A$0.72 — trading 62.5% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 71.50, which is near median its 10-year median of 75.25 and 1101.7% above the Biotechnology industry median of 5.95. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Cyclically Adjusted PS Ratio is 71.50 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?
Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued.
The current stock price of A$0.72 is trading 62.5% above its estimated GF Value™ of A$0.44.
GuruFocus considers Starpharma Holdings to be Significantly Overvalued.
Key valuation signals for ASX:SPL:
Cyclically Adjusted PS Ratio: 71.50 (near median its 10-year median of 75.25)
GF Value™: A$0.44 vs. price of A$0.72 (62.5% above fair value)
Industry Position: 1101.7% above the Biotechnology median (#493 of 535)
No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score
Get the complete analysis for ASX:SPL
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SPL has been successfully added to your 
